Gene-Tailored cancer drugs fail to outperform standard care in large trial
NCT ID NCT01771458
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 15 times
Summary
This study tested whether choosing cancer drugs based on the genetic profile of a patient's tumor could help people with advanced solid tumors live longer without their cancer growing. Over 700 adults whose cancer had stopped responding to standard treatments were randomly assigned to receive either a targeted therapy matched to their tumor's molecular abnormalities or the doctor's choice of conventional therapy. The results help researchers understand the value of molecular profiling for guiding treatment decisions in hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECCURENT/METASTATIC SOLID TUMOR DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Alexis Vautrin
Vandœuvre-lès-Nancy, 54500, France
-
Centre Leon Berard
Lyon, 69373, France
-
Centre régional de lutte contre le cancer de Bourgogne Georges François Leclerc
Dijon, 21079, France
-
Insitut Curie
Paris, 75248, France
-
Institut Claudius Régaud
Toulouse, 31052, France
-
Institut Curie Hopital Rene Huguenin
Saint-Cloud, 92210, France
-
Institut Paoli Calmettes
Marseille, 13009, France
-
Institut de cancérologie de l'Ouest Centre René Gauducheau
Saint-Herblain, 44000, France
Conditions
Explore the condition pages connected to this study.